| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 152, Issue 10 4958-4968, Copyright © 1994 by American Association of Immunologists
ARTICLES |
J Mullberg, W Oberthur, F Lottspeich, E Mehl, E Dittrich, L Graeve, PC Heinrich and S Rose-John
Department of Biochemistry, Rheinisch-Westfalische Technische Hochschule Aachen, Germany.
Like many proteins with a single transmembrane domain the IL-6R exists in a membrane-associated and soluble form. The soluble IL-6R is generated by limited proteolysis of the membranous receptor. This process, also called shedding, is drastically enhanced by PMA, an activator of protein kinase C. The soluble receptor protein was purified to homogeneity from supernatants of COS-7 cells transfected with a cDNA coding for the transmembrane IL-6R. The COOH-terminus of the shed receptor protein was analyzed by carboxypeptidase treatment and subsequent amino acid analysis. The established cleavage site Gln357/Asp358 was extensively altered by point mutations and small deletions to define the structural requirements for cleavage. Although point mutations around the cleavage site reduced shedding of the IL-6R up to fivefold, deletions of 5 or 10 amino acids almost completely abolished shedding. Deletion of the cytoplasmic domain of the receptor had no influence on shedding of the protein. It turned out that a potential N-glycosylation site close to the proteolytic cleavage site of the IL-6R is used. However this N-glycosylation does not affect the efficiency of the shedding process. Furthermore, we demonstrate for the first time that the human IL-6R is constitutively phosphorylated and that this phosphorylation can be stimulated by PMA but is not correlated with shedding of the receptor protein. The knowledge of the mechanism by which the soluble IL-6R is generated will help to identify the processing enzyme involved and to analyze its regulation.
This article has been cited by other articles:
|
|
 |
|
  M. Hashizume, N. Hayakawa, and M. Mihara IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-{alpha} and IL-17 Rheumatology, September 11, 2008; (2008) ken363v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ellingsgaard, J. A. Ehses, E. B. Hammar, L. Van Lommel, R. Quintens, G. Martens, J. Kerr-Conte, F. Pattou, T. Berney, D. Pipeleers, et al. Interleukin-6 regulates pancreatic {alpha}-cell mass expansion PNAS, September 2, 2008; 105(35): 13163 - 13168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Briso, O. Dienz, and M. Rincon Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells J. Immunol., June 1, 2008; 180(11): 7102 - 7106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Porta, M. De Amici, S. Quaglini, C. Paglino, F. Tagliani, A. Boncimino, R. Moratti, and G. R. Corazza Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma Ann. Onc., February 1, 2008; 19(2): 353 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Rabe, A. Chalaris, U. May, G. H. Waetzig, D. Seegert, A. S. Williams, S. A. Jones, S. Rose-John, and J. Scheller Transgenic blockade of interleukin 6 transsignaling abrogates inflammation Blood, February 1, 2008; 111(3): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Qi, N. Rifai, and F. B. Hu Interleukin-6 Receptor Gene Variations, Plasma Interleukin-6 Levels, and Type 2 Diabetes in U.S. Women Diabetes, December 1, 2007; 56(12): 3075 - 3081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Bustamante, X Nogues, L Mellibovsky, L Agueda, S Jurado, E Caceres, J Blanch, R Carreras, A Diez-Perez, D Grinberg, et al. Polymorphisms in the interleukin-6 receptor gene are associated with bone mineral density and body mass index in Spanish postmenopausal women Eur. J. Endocrinol., November 1, 2007; 157(5): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sather, K. D. Kenyon, J. B. Lefkowitz, X. Liang, B. C. Varnum, P. M. Henson, and D. K. Graham A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation Blood, February 1, 2007; 109(3): 1026 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Cozen, M. Gebregziabher, D. V. Conti, D. J. Van Den Berg, G. A. Coetzee, S. S. Wang, N. Rothman, L. Bernstein, P. Hartge, A. Morhbacher, et al. Interleukin-6-Related Genotypes, Body Mass Index, and Risk of Multiple Myeloma and Plasmacytoma. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2285 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, Z. Zhang, W. Chu, T. Hale, J. J. Cooper, and S. C. Elbein Molecular Screening and Association Analyses of the Interleukin 6 Receptor Gene Variants with Type 2 Diabetes, Diabetic Nephropathy, and Insulin Sensitivity J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1123 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Hamid, S. A. Urhammer, D. P. Jensen, C. Glumer, K. Borch-Johnsen, T. Jorgensen, T. Hansen, and O. Pedersen Variation in the Interleukin-6 Receptor Gene Associates With Type 2 Diabetes in Danish Whites Diabetes, December 1, 2004; 53(12): 3342 - 3345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Tsakadze, U. Sen, Z. Zhao, S. D. Sithu, W. R. English, and S. E. D'Souza Signals mediating cleavage of intercellular adhesion molecule-1 Am J Physiol Cell Physiol, July 1, 2004; 287(1): C55 - C63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Shariat, M. W. Kattan, E. Traxel, B. Andrews, K. Zhu, T. M. Wheeler, and K. M. Slawin Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor {beta}1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression Clin. Cancer Res., March 15, 2004; 10(6): 1992 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Matthews, B. Schuster, S. Schutze, I. Bussmeyer, A. Ludwig, C. Hundhausen, T. Sadowski, P. Saftig, D. Hartmann, K.-J. Kallen, et al. Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE) J. Biol. Chem., October 3, 2003; 278(40): 38829 - 38839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kang, H. I. Park, Y. Suh, Y.-G. Zhao, H. Tschesche, and Q.-X. A. Sang Autolytic Processing at Glu586-Ser587 within the Cysteine-rich Domain of Human Adamalysin 19/Disintegrin-Metalloproteinase 19 Is Necessary for Its Proteolytic Activity J. Biol. Chem., December 6, 2002; 277(50): 48514 - 48522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Giri, M. Ozen, and M. Ittmann Interleukin-6 Is an Autocrine Growth Factor in Human Prostate Cancer Am. J. Pathol., December 1, 2001; 159(6): 2159 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Elhabazi, S. Delaire, A. Bensussan, L. Boumsell, and G. Bismuth Biological Activity of Soluble CD100. I. The Extracellular Region of CD100 Is Released from the Surface of T Lymphocytes by Regulated Proteolysis J. Immunol., April 1, 2001; 166(7): 4341 - 4347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. JONES, S. HORIUCHI, N. TOPLEY, N. YAMAMOTO, and G. M. FULLER The soluble interleukin 6 receptor: mechanisms of production and implications in disease FASEB J, January 1, 2001; 15(1): 43 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Mei{beta}ner, H. Blum, M. Schnare, M. Rollinghoff, and A. Gessner A soluble form of the murine common {gamma} chain is present at high concentrations in vivo and suppresses cytokine signaling Blood, January 1, 2001; 97(1): 183 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. GALUN, E. ZEIRA, O. PAPPO, M. PETERS, and S. ROSE-JOHN Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury FASEB J, October 1, 2000; 14(13): 1979 - 1987. [Abstract] [Full Text]
|
|
|
|
|
|
J. R. Doedens and R. A. Black Stimulation-induced Down-regulation of Tumor Necrosis Factor-alpha Converting Enzyme J. Biol. Chem., May 5, 2000; 275(19): 14598 - 14607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Reddy, J. L. Slack, R. Davis, D. P. Cerretti, C. J. Kozlosky, R. A. Blanton, D. Shows, J. J. Peschon, and R. A. Black Functional Analysis of the Domain Structure of Tumor Necrosis Factor-alpha Converting Enzyme J. Biol. Chem., May 5, 2000; 275(19): 14608 - 14614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Murase, N. Kume, H. Kataoka, M. Minami, T. Sawamura, T. Masaki, and T. Kita Identification of Soluble Forms of Lectin-Like Oxidized LDL Receptor-1 Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 715 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lammich, E. Kojro, R. Postina, S. Gilbert, R. Pfeiffer, M. Jasionowski, C. Haass, and F. Fahrenholz Constitutive and regulated alpha -secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease PNAS, March 30, 1999; 96(7): 3922 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roghani, J. D. Becherer, M. L. Moss, R. E. Atherton, H. Erdjument-Bromage, J. Arribas, R. K. Blackburn, G. Weskamp, P. Tempst, and C. P. Blobel Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity J. Biol. Chem., February 5, 1999; 274(6): 3531 - 3540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Schlondorff and C. Blobel Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding J. Cell Sci., January 11, 1999; 112(21): 3603 - 3617. [Abstract] [PDF]
|
|
|
|
|
|
S. de Bernard, M. Misrahi, J.-C. Huet, I. Beau, A. Desroches, H. Loosfelt, C. Pichon, J.-C. Pernollet, and E. Milgrom Sequential Cleavage and Excision of a Segment of the Thyrotropin Receptor Ectodomain J. Biol. Chem., January 1, 1999; 274(1): 101 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Hartwell, T. N. Mayadas, G. Berger, P. S. Frenette, H. Rayburn, R. O. Hynes, and D. D. Wagner Role of P-Selectin Cytoplasmic Domain in Granular Targeting In Vivo and in Early Inflammatory Responses J. Cell Biol., November 16, 1998; 143(4): 1129 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peters, A. M. Muller, and S. Rose-John Interleukin-6 and Soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis Blood, November 15, 1998; 92(10): 3495 - 3504. [Full Text] [PDF]
|
|
|
|
|
|
J.-W. Oh, N. J. Van Wagoner, S. Rose-John, and E. N. Benveniste Role of IL-6 and the Soluble IL-6 Receptor in Inhibition of VCAM-1 Gene Expression J. Immunol., November 1, 1998; 161(9): 4992 - 4999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Marz, J.-G. Cheng, R. A. Gadient, P. H. Patterson, T. Stoyan, U. Otten, and S. Rose-John Sympathetic neurons can produce and respond to interleukin 6 PNAS, March 17, 1998; 95(6): 3251 - 3256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kamitani, H. P. Nguyen, and E. T. H. Yeh Activation-induced Aggregation and Processing of the Human Fas Antigen. DETECTION WITH CYTOPLASMIC DOMAIN-SPECIFIC ANTIBODIES J. Biol. Chem., August 29, 1997; 272(35): 22307 - 22314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Subramanian, M. L. Fitzgerald, and M. Bernfield Regulated Shedding of Syndecan-1 and -4 Ectodomains by Thrombin and Growth Factor Receptor Activation J. Biol. Chem., June 6, 1997; 272(23): 14713 - 14720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Arribas, L. Coodly, P. Vollmer, T. K. Kishimoto, S. Rose-John, and J. Massagué Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors J. Biol. Chem., May 10, 1996; 271(19): 11376 - 11382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Feehan, K. Darlak, J. Kahn, B. Walcheck, A. F. Spatola, and T. K. Kishimoto Shedding of the Lymphocyte L-Selectin Adhesion Molecule Is Inhibited by a Hydroxamic Acid-based Protease Inhibitor J. Biol. Chem., March 22, 1996; 271(12): 7019 - 7024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Garton, P. J. Gough, C. P. Blobel, G. Murphy, D. R. Greaves, P. J. Dempsey, and E. W. Raines Tumor Necrosis Factor-alpha -converting Enzyme (ADAM17) Mediates the Cleavage and Shedding of Fractalkine (CX3CL1) J. Biol. Chem., October 5, 2001; 276(41): 37993 - 38001. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
